These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 35605841)
1. Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function. de Cacqueray N; Hirt D; Zheng Y; Bille E; Leger PL; Rambaud J; Toubiana J; Chosidow A; Vimont S; Callot D; Chouchana L; Béranger A; Tréluyer JM; Benaboud S; Oualha M Clin Microbiol Infect; 2022 Oct; 28(10):1389.e1-1389.e7. PubMed ID: 35605841 [TBL] [Abstract][Full Text] [Related]
2. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance. Béranger A; Benaboud S; Urien S; Moulin F; Bille E; Lesage F; Zheng Y; Genuini M; Gana I; Renolleau S; Hirt D; Tréluyer JM; Oualha M Clin Pharmacokinet; 2019 Feb; 58(2):223-233. PubMed ID: 29862466 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients. An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Patel PC; Fishbane N; Watanabe A; Rolsma S; Kirkpatrick CMJ; Landersdorfer CB; Winokur P J Antimicrob Chemother; 2023 Jun; 78(6):1460-1470. PubMed ID: 37071586 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study. Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus. Salvador E; Oualha M; Bille E; Beranger A; Moulin F; Benaboud S; Boujaafar S; Gana I; Urien S; Zheng Y; Toubiana J; Briand C; Bustarret O; Geslain G; Renolleau S; Treluyer JM; Hirt D Clin Microbiol Infect; 2021 Mar; 27(3):413-419. PubMed ID: 32360445 [TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155 [TBL] [Abstract][Full Text] [Related]
7. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients. Bilal M; Zoller M; Fuhr U; Jaehde U; Ullah S; Liebchen U; Büsker S; Zander J; Babouee Flury B; Taubert M Antimicrob Agents Chemother; 2023 Jul; 67(7):e0030923. PubMed ID: 37366614 [TBL] [Abstract][Full Text] [Related]
8. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy. Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162 [TBL] [Abstract][Full Text] [Related]
9. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy. Thy M; Urien S; Foissac F; Bouazza N; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M Antimicrob Agents Chemother; 2022 Dec; 66(12):e0113522. PubMed ID: 36342152 [TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children. Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of meropenem in critically ill children with different renal functions. Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149 [TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Monte Carlo Simulation of Cefepime in Critically Ill Patients with Hospital-Acquired/Ventilator-Associated Pneumonia. Seo H; Kim YK; Park S; Kim HI; Lee DH Infect Chemother; 2023 Mar; 55(1):29-41. PubMed ID: 36450287 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). Kois AK; Gluck JA; Nicolau DP; Kuti JL Int J Antimicrob Agents; 2022 Jul; 60(1):106603. PubMed ID: 35577257 [TBL] [Abstract][Full Text] [Related]
14. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy. Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885 [TBL] [Abstract][Full Text] [Related]
15. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy. Pavia K; Hambrick HR; Paice K; Tang P; Punt N; Kaplan J; Goldstein SL; Vinks AA; Mizuno T; Tang Girdwood S J Antimicrob Chemother; 2023 Sep; 78(9):2140-2147. PubMed ID: 37466170 [TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy. Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Jakob SM; Levkovich BJ; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Roberts JA; Shekar K; Fraser JF Int J Antimicrob Agents; 2021 Dec; 58(6):106466. PubMed ID: 34688834 [TBL] [Abstract][Full Text] [Related]
18. Monte Carlo simulations of cefepime in children receiving continuous kidney replacement therapy support continuous infusions for target attainment. Hambrick HR; Punt N; Pavia K; Mizuno T; Goldstein SL; Tang Girdwood S J Intensive Care; 2024 Oct; 12(1):38. PubMed ID: 39380059 [TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children. Sridharan K; Abbasi MY; Mulubwa M Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):539-546. PubMed ID: 34156647 [TBL] [Abstract][Full Text] [Related]
20. Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation. Morales Junior R; Mizuno T; Paice KM; Pavia KE; Hambrick HR; Tang P; Jones R; Gibson A; Stoneman E; Curry C; Kaplan J; Tang Girdwood S J Antimicrob Chemother; 2024 Oct; 79(10):2668-2677. PubMed ID: 39092928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]